Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy

Article English OPEN
Merlini L; Cartenì G; Iacobelli S; Stelitano C; Airoldi M; Balcke P; Keil F; Haslbauer F; Belton L; Pujol B;
  • Publisher: Dove Press
  • Journal: Cancer Management and Research, volume 5, pages 205-214 (issn: 1179-1322, eissn: 1179-1322)
  • Publisher copyright policies & self-archiving
  • Related identifiers: doi: 10.2147/CMAR.S45236, pmc: PMC3739422
  • Subject: management | RC254-282 | Cancer Management and Research | iron | Original Research | transfusion | hemoglobin | Neoplasms. Tumors. Oncology. Including cancer and carcinogens | erythropoiesis-stimulating agent

Laura Merlini,1 Giacomo Cartenì,2 Stefano Iacobelli,3 Caterina Stelitano,4 Mario Airoldi,5 Peter Balcke,6 Felix Keil,7 Ferdinand Haslbauer,8 Laura Belton,9 Beatriz Pujol10 1Department of Medical Oncology, Ospedale Civile S, Bortolo, Vicenza, 2Department of... View more
  • References (15)
    15 references, page 1 of 2

    1. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-2306.

    2. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42(15): 2433-2453.

    3. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001;91(12):2214-2221.

    4. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome. Oncology. 2005;69 Suppl 2:2-7.

    5. Calabrich A, Katz A. Management of anemia in cancer patients. Future Oncol. 2011;7(4):507-517.

    6. Aapro MS, Link H. Sep 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13 Suppl 3:33-36.

    7. Schrijvers D, De Samblanx H, Roila F; for ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol. 2010;21 Suppl 5:v244-v247.

    8. Aapro M, Österborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and management of cancer-related anaemia, iron decfiiency and the specicfi role of i.v. iron. Ann Oncol. 2012;23(8):1954-1962.

    9. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011;16 Suppl 3:12-18.

    10. Amgen Europe BV.Aranesp® Annex I Summary of Product Characteristics. TheNetherlands:AmgenEuropeBV;2012.Availablefrom:http://www.ema. human/000332/WC500026149.pdf. Accessed June 27, 2013.

  • Related Organizations (2)
  • Metrics
Share - Bookmark